Racecadotril versus loperamide: Antidiarrheal research revisited

Digestive Diseases and Sciences

Volumn 48, Issue 2, 2003, Pages 239-250

  Huijghebaert, S ^a   Awouters, F ^b   Tytgat, G N J ^c  

^a Consultant Pharmaceutical Sciences ^*  (Belgium)

^b Center for Molecular Design   (Belgium)

^c ACADEMIC MEDICAL CENTER   (Netherlands)

Author keywords

Antidiarrheal; Antisecretory; Diarrhea; Loperamide; Racecadotril

Indexed keywords

ACETORPHAN; ANTIBIOTIC AGENT; BISMUTH SALICYLATE; CHOLERA TOXIN; ENKEPHALIN; ENKEPHALINASE INHIBITOR; LOPERAMIDE; MEMBRANE METALLOENDOPEPTIDASE; NALOXONE; OCTREOTIDE; OPIATE AGONIST; PROBIOTIC AGENT; STOMACH SECRETION INHIBITOR; THIORPHAN;

ABDOMINAL DISTENSION; ADULT; ANIMAL MODEL; BACTERIAL GROWTH; BLOOD LEVEL; CENTRAL NERVOUS SYSTEM DISEASE; CLINICAL RESEARCH; CLINICAL TRIAL; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DROWSINESS; DRUG EFFICACY; DRUG POTENCY; DRUG SELECTIVITY; DRUG TOLERABILITY; GASTROINTESTINAL MOTILITY; GASTROINTESTINAL TRANSIT; HUMAN; ILEUS; IN VITRO STUDY; INFANT; NONHUMAN; PRIORITY JOURNAL; PUBLICATION; RELIABILITY; REVIEW; SIDE EFFECT; TREATMENT CONTRAINDICATION; TREATMENT OUTCOME; VALIDATION PROCESS;

ADOLESCENT; ADULT; ANTIDIARRHEALS; CHILD; CHILD, PRESCHOOL; CONTROLLED CLINICAL TRIALS; DIARRHEA; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; FEMALE; FOLLOW-UP STUDIES; HUMANS; INFANT; LOPERAMIDE; MALE; MIDDLE AGED; SEVERITY OF ILLNESS INDEX; THIORPHAN; TREATMENT OUTCOME;

EID: 0037324156     PISSN: 01632116     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1021989606317     Document Type: Review

References (113)

1. Farthing MJG: Introduction. Enkephalinase inhibition: a rational approach to antisecretory therapy for acute diarrhoea. Aliment Pharmacol Ther 13(suppl 6):1-2, 1999
2. Primi MP, Bueno L, Baumer P, Berard H, Lecomte JM: Racecadotril demonstrates intestinal antisecretory activity in vivo. Aliment Pharmacol Ther 13(suppl 6):3-7, 1999
3. Duval-Iflah Y, Berard H, Baumer P. Guillaume P, Raibaud P, Joulin Y, Lecomte JM: Effects of racecadotril and loperamide on bacterial proliferation and on the central nervous system of the newborn gnotobiotic piglet. Aliment Pharmacol Ther 13(suppl 6):9-14, 1999
4. Hamza H, Ben Khalifa H, Baumer P, Berard H, Lecomte JM: Racecadotril versus placebo in the treatment of acute diarrhoea in adults. Aliment Pharmacol Ther 13(suppl 6):15-19, 1999
5. Vetel JM, Berard H, Fretault N, Lecomte JM: Comparison of racecadotril and loperamide in adults with acute diarrhoea. Aliment Pharmacol Ther 13(suppl 6):21-26, 1999
6. Turck D, Berard H, Fretault N, Lecomte JM: Comparison of racecadotril and loperamide in children with acute diarrhoea. Aliment Pharmacol Ther 13(suppl 6):27-32, 1999
7. Farthing MJ: Diarrhea: a significant worldwide problem. Int J Antimicrob Agents 14:65-69, 2000
8. Lecomte JM: Symposium on the treatment of diarrheal disease. An overview of clinical studies with racecadotril in adults. Int J Antimicrob Agents 14:81-87, 2000
9. Matheson AJ, Noble S: Racecadotril. Adis new drug Profile. Drugs 59:829-835, 2000
10. Schwartz JC: Racecadotril: a new approach to the treatment of diarrhoea. Int J Antimicrob Agents 14:75-79, 2000
11. Bioproject Pharma: Package insert, Tiorfan. Paris, France
12. SmithKline Beecham Int. Hidrasec racecadotril. Rapid physiological control in acute diarrhoea. Product monograph, Brentford, England, Author, 1998.
13. Turvill J, Farthing M: Enkephalins and enkephalinase inhibitors in intestinal fluid and electrolyte transport. Eur J Gastroenterol Hepatol 9:877-880, 1997
14. Baumer Ph, Danquechin Dorval E, Bertrand J, Vetel JM, Shwartz JC, Lecomte JM: Effects of acetorphan, an enkephalinase inhibitor on experimental and acute diarrhoea. Gut 33:753-758, 1992
15. Bergmann JF, Chaussade S, Couturier D, Baumer P, Schwartz JC, Lecomte JM: Effects of acetorphan, an antidiarrhoeal enkephalinase inhibitor, on oro-caecal and colonic transit times in healthy volunteers. Aliment Pharmacol Ther 6:305-313, 1992
16. Schiller LR: Anti-diarrhoeal pharmacology and therapeutics. Aliment Pharmacol Ther 9:87-106, 1995
17. Dhawan BN, Cesselin F, Raghubir R, Reisine T, Bradley PB, Portoghese PS, Hamon M: International Union of Pharmacology, XII Classification of opioid receptors. Pharmacol Rev 48:567-592, 1996
18. Lord JAH, Waterfield AA, Hughes J, Kosterlitz HW: Endogenous opioid peptides: multiple agonists and receptors. Nature 267:495-499, 1977
19. Coupar IM: The peristaltic reflex in the rat ileum: evidence for functional μ-and δ-opiate receptors. J Pharm Pharmacol 47:643-646, 1995
20. Rachmilewitz D, Karmeli F, Chorev M, Selinger Z: Effects of opiates on human colonic adenylate cyclase activity. Eur J Pharmacol 93:169-173, 1983
21. Turnberg LA: Control of intestinal transport by the central nervous system. In Control of Intestinal Transport by the Central Nervous System. The Relationhips Between Intestinal Motility and Epithelial Transport. NW Read (ed). Procedings, International. Workshop, Dorado, Puerto Rico, January 1985), Janssen Research Council, Beerse, Belgium. pp. 269-273
22. De Luca A, Coupar IM: Insights into opioid action in the intestinal tract. Pharmacol Ther 69:103-115, 1996
23. Beleslin DB, Terzic B, Samardzic R: The effect of leucine-enkephalin on the peristaltic reflex of the isolated guinea-pig ileum. Acta Physiol Hung 69:105-114, 1987
24. Venkova K, Radomirov R, Pencheva N: Effects of leu-enkephalin on the mechanical activity of longitudinal and circular muscles of the small intestine of the cat. Neuropharmacology 28:1183-1191, 1989
25. Schemann M, Ehrlein HJ: Effects of neurohormonal agents on jejunal contraction spread and transit in the fed dog. Gastroenterology 90(6):1950-1955, 1986
26. Wienbeck M, Blasberg M: Effects of enkephalin analog on motility of the small and large intestine in the cat. Z Gastroenterol 24(4):179-187, 1986
27. Broccardo M, Improta G, Tabacco A: Central effect of SNC 80, a selective and systematically active delta-opioid receptor agonist, on gastrointestinal propulsion in the mouse. Eur J Pharmacol 342:247-251, 1998
28. Herbrecht F, Bagnol D, Cucumel K, Jule Y, Cupo A: Distribution of enkephalin immunoreactivity in sympathetic prevertebral ganglia and digestive tract of guinea-pigs and rats. Regul Pept 57(1):85-95, 1995
29. Rinne JO, Lönnberg P, Marjamäki P: Human brain methionine- and leucine-enkephalins and their receptors during ageing. Brain Res 624:131-136, 1993
30. Villiger JW, Taylor KM, Gluckman PD: Ontogenesis of opiate receptors in regions of the ovine brain. Pediatr Pharmacol (New York) 2(4):349-356, 1982
31. Martinez AM, Padbury JF, Burnell EE, Thio SL: Plasma methionine enkephalin levels in the human newborn at birth. Biol Neonate 60(2):102-107, 1991
32. Oka T, Liu XF, Kajita T, Ohgiya N, Ghoda K, Taniguchi T, Arai Y, Matsumiya T: Effects of the subcutaneous administration of enkephalins on tail-flick response and righting reflex of developing rats. Brain Res Dev Brain Res 69:271-276, 1992
33. 3H]DAGO) binding sites in rat hypothalamus and ex vivo determination of blood-brain barrier penetration by opioid peptide FK 33-824. Brain Res Dev Brain Res 54(2):169-176, 1990
34. Banks WA, Kastin AJ: Aging and the blood-brain barrier: changes in the carrier-mediated transport of peptides in rats. Neurosci Lett 61(1-2):171-175, 1985
35. Marini M, Urbani A, Trani E, Bongiorno L, Roda LG: Interindividual variability of enkephalin-degrading enzymes in human plasma. Peptides 18(5):741-748, 1997
36. Money SR, Petrolanu A, Ginzler AR, Jaffe BM: Meal-stimulated release of methionine- enkephalin into the canine jejunal lumen. J Clin Invest 81:822-825, 1988
37. Klin M, Waluga M, Rudka R, Madej A, Zaniszewska M, Grzebieniak E, Wesolowky A: Plasma catecholamines, neuropeptide Y and leucine-enkephalin in uremic patients before and after dialysis during rest and handgrip. Bull Chim Farm 137(8):306-313, 1998
38. Gui X, Pan G, Ke M: Potential role of gut peptides in stress-induced colonic motor disorder. Chung Hua I Hsueh Tsa Chih 77(1):313-314, 1997 (English Abstract)
39. Bongiorno L, Fuso L, Marini M, Marzano M, Nardecchia B, Marzano M, Nardecchia B, Roda GL, Rossi P, Urbani U: Leucine enkephalin degradation in allergopathic versus normal human plasma. Immunopharmacology 39(2):93-105, 1998
40. Fontana F, Bernardi P, Spampinato S, Boschi S, De Iasio R, Grossi G: Pressor effects of endogenous opioid system during acute episodes of blood pressure in hypertensive patients. Hypertension 29:105-110, 1997
41. El-Salhy M, Norrgard O: Colonic neuroendocrine peptide levels in patients with chronic idiopathic slow transit constipation. Ups J Med Sci 103:223-230, 1998
42. Marçais-Collado H, Uchida G, Costentin J, Schwartz JC, Lecomte JM: Naloxone-reversible antidiarrheal effects of enkephalinase inhibitors. Eur J Pharmacol 144:125-132, 1987
43. Babst R, Bongiorno L, Marini M, Marzano M, Spagnoli G, Urbani A: Age-induced increase of leucine enkephalin enzyme degradation in human plasma. Peptides 19(7):1155-1163, 1998
44. Bongiorno L, Marzano M, Marini M, Roda LG, Urbani A, Spagnoli G: Age increases leucine enkephalin hydrolysis in human plasma. Gerontology 45(1):10-16, 1999
45. Lecomte JM, Costentin J, Vlaiculescu A, Chailet P, Marcais-Collado H, Llorens-Cortes C, Leboyer M, Schwartz J-C: Pharmacological properties of acetorphan, a parenterally active enkephalinase inhibitor. J Pharmacol Exp Ther 237:937-944, 1986
46. Fioramonti J, Buno L, Hargeas MJ: Enhancement of the colonic motor response to feeding by central endogenous opiates in the dog. Life Sci 36:2509-2514, 1985
47. Benouali S, Roche M, Berard H, Lecomte JM: Electromyographic pattern of colonic motility induced by acetorphan in the rat. Gastroenterology 102:A424, 1992
48. Riviére PJ, Liberge M, Murillo-Lopez D, Bueno L: Opposite central and peripheral control by endogenous opioids of intestinal motility in fed rats. Br J Pharmacol 98(1):236-342, 1989
49. Niemegeers CJE, Awouters F, Lenaerts FM, Artois KSK, Vermeire J: Antidiarrhoeal specificity and safety of the N-oxide of loperamide (R 58 425) in rats. Drug Development Research 8:279-286, 1986
50. Megens AAHP, Canters LLJ, Awouters FHL, Niemegeers FHL: Is in vivo dissociation between the antipropulsive and antidiarrhoeal properties opioids in rats related to gut selectivity? Arch Int Pharmacodyn Ther 298:220-229, 1989
51. Lavrijsen K, Van Dyck D, Van Houdt J, Hendrickx J, Monbaliu J, Woestenborghs R, Meuldermans W, Heykants J: Reduction of the prodrug loperamide oxide to its active drug loperamide in the gut of rats, dogs and humans. Drug Metab Dispos 23:354-362, 1995
52. van Amsterdam JG, van Buuren KJ, Krielaart MJ, Zuiderveld OP, Tijms RP: Effects of inhibitors of enkephalin degradation in the isolated guinea-pig ileum. Life Sci 43(19):1529-1536, 1988
53. Korner MM, Wienbeck M: Differential effects of loperamide on gut motility. Gastroenterology 82:1255, 1982
54. Kachel G, Ruppin H, Hagel J, Barina W, Meinhardt M, Domschke W: Human intestinal motor activity and transport: effects of a synthetic opiate. Gastroenterology 90:85-93, 1986
55. Karaus M, Enck P, Erchenbrecht JF, Stromeyer G: Loperamide and its prodrug lopoxyde have different effects on small and large bowel motility. Gastroenterology 98:A364, 1990
56. Telford GL, Varner DE, McManus LL, Walgenbach-Telford S, Otterson MF, Condon RE, Sarna SK: Effect of daily loperamide administration on gastro-intestinal myoelectric activity. J Gastrointest Motil 4:25-31, 1992
57. Awouters F, Megens A, Verlinden M, Schuurkes J, Niemegeers C, Janssen PA: Loperamide. Survey of studies on mechanism of its antidiarrheal activity. Dig Dis Sci 38:977-995, 1993
58. Rees WDW, Sharpe GR, Christofides ND, Bloom SR, Turnberg LA. The effects of an opiate agonist and antagonist on the human upper gastro-intestinal tract. Eur J Clin Invest 13:221-225, 1983
59. Stacher G, Steinringer H, Schneider C, Vacariu-Granser GV, Castiglione F, Gaupmann G, Weber U, Stacher-Janotta G: Effects of the prodrug loperamide oxide, loperamide and placebo on jejunal motor activity. Dig Dis Sci 37:198-204, 1992
60. Kirby MG, Dukes GE, Heizer WD, Bryson JC, Powel JR: Effects of metoclopramide, betanechol, and loperamide on gastric residence time, gastric emptying and mouth-to-caecum transit time. Pharmacotherapy 9(4):226-231, 1989
61. Van Wyk M, Sommers DK, Steyn GW: Evaluation of gastrointestinal motility using the hydrogen breath test. Br J Clin Pharmacol 20:479-481, 1985
62. El Oufir L, Flourié B, Bruley des Varannes S, Barry JL, Cloarec D, Bornet F, Galmiche JP: Relations between transit time, fermentation products and hydrogen consuming flora in healthy humans. Gut 38:870-877, 1996
63. Corbett CL, Thomas S, Read NW, Hobson N, Bergman I, Holdsworth CD: Electrochemical detector for breath hydrogen determination: measurement of small bowel transit time in normal subjects and patients with the irritable bowel syndrome. Gut 22:836-840, 1981
64. Keeling WF, Harris A, Martin BJ: Loperamide abolishes exercise-induced orocecal liquid transit acceleration. Dig Dis Sci 38(10):1783-1787, 1993
65. Lambert-Zechovsky N, Cezard JP, Bingen E, Mashako L, Marinier E, Navarro J: Effect of loperamide on faecal flora in infants with severe protracted diarrhoea. Acute infectious diarrhoea: role of drug therapy, HL DuPont 1997. In Proceedings of an International Symposium (ed). Held at the IXth International Congress of Infectious and Parasitic Diseases. Munich, July 21, 1986
66. Remington M, Malagelada J-R, Zinmeister A, Fleming CR: Abnormalities in gastrointestinal motor activity in patients with short bowels: effect of a synthetic opiate. Gastroenterology 85:629-636, 1983
67. Banks MR, Bose M, Farthing JG: The effects of the enkephalinase inhibitor racecadotril on enterotoxin-induced intestinal secretion in the rat. Gut 47 (suppl III):A48 2000
68. Hinterleitner TA, Petritsch W, Dimsity G, Berard H, Lecomte JM, Krejs GJ: Acetorphan prevents cholera-toxin-induced water and electrolyte secretion in the human jejunum. Eur J Gastroenterol Hepatol 9:887-891, 1997
69. Farack UM, Kautz U, Loeschke K: Loperamide reduces the intestinal secretion but not the mucosal cAMP accumulation induced by cholera toxin. Naunyn-Schmiedeberg's Arch Pharm 317:178-179, 1981
70. Dashwood MR, Sykes RM, Thomson CS: Autoradiographic demonstration of [3H]loperamide binding to opioid receptors in rat and human small intestine. Int Narcotics Res Conf 89:165-169, 1990
71. Burleigh DE: Loperamide but not morphine has anti-secretory effects in human colon, in vitro. Eur J Pharmacol 202:277-280, 1991
72. Hughes S, Higgs NB, Turnberg LA: Loperamide has antisecretory activity in the human jejunum in vivo. Gut 25:931-935, 1984
73. 2-induced secretion and intestinal transit time in man. Eur J Clin Pharmacol 41:239-243, 1991
74. Stoll R, Ruppin H, Domschke W: Calmodulin mediated effects of loperamide on chloride transport by brush border membrane vesicles from human ileum. Gastroenterology 95:69-76, 1988
75. Spillantini MG, Sicuteri F, Salmon S, Malfroy B: Characterization of endopeptidase 3.4.24.11 (enkephalinase) activity in human plasma and cerebrospinal fluid. Biochem Pharmacol 39:1353-1356, 1990
76. Spillantini MG, Gepetti P, Fanciullacci M, Michelacci S, Lecompte JM, Sicuteri F: In vivo enkephalinase inhibition by acetorphan in human plasma and CSF. Eur J Pharmacol 125:147-150, 1986
77. Geppetti P, Spillantini MG, Frilli S, Pietrini U, Fanciullacci M, Sicuteri F: Acute oral captopril inhibits angiotensin converting enzyme in human cerebrospinal fluid. J Hypertens 5:151-154, 1987
78. 3H] acetorphan as a probe. J Pharmacol Exp Ther 247(2):653-660, 1988
79. Giros B, Llorens-Cortes C, Gros C, Schwartz JC: The endogenous tripeptide Tyr-Gly-Gly as a possible metabolite of opioid peptides in rat brain: identification, regional distribution, effects of lesions and formation in depolarized slices. Peptides 7(4):669-677, 1986
80. Kayser V, Fournie-Zaluski MC, Guilbaud G, Roques BP: Potent antinociceptive effects of kelatorphan (a highly efficient inhibitor of multiple enkephalin-degrading enzymes) systemically administered in normal and arthritic rats. Brain Res 497(1):94-101, 1989
81. Malin DH, Lake JR, Hamilton RF, Skolnick MH: Augmented analgesic effects of enkephalinase inhibitors combined with transcranial electrostimulation. Life Sci 44(19):1371-1376, 1989
82. Bado A, Chicau-Chovet M, Appia F, Dubrasquet M, Lecomte JM, Roze C: Acetorphan, an enkephalinase inhibitor, decreases gastric secretion in cats. Peptides 8:89-93, 1987
83. Chicau-Chovet M, Dubrasquet M, Chariot J, Tsocas A, Lecomte JM, Roze C: Thiorphan and acetorphan inhibit gastric secretion by a central, non-opioid mechanism in the rat. Eur J Pharmacol 154:247-254, 1988
84. Livingston SJ, Sewell RD, Rooney KF, Smith HJ: Amelioration of naloxone-precipitated opioid withdrawal symptoms by peripheral administration of the enkephalinase inhibitor acetorphan. Psychopharmacology 94(4):540-544, 1988
85. Dzoljic MR, Bokszanska A, Korenhof AM, Kaplan CD, Dzoljic M, Rupreht J, Zijlstra FJ, Brinkman EC, Cappendijk SL: The effects of orally active enkephalinase inhibitors on morphine withdrawal syndrome. Neuroreport 3(7):637-640, 1992
86. Wüster M, Herz A: Opiate agonist action of antidiarrhoeal agents in vitro and in vivo.-Finding in support of selective action. Naunyn. Schmied Arch Pharm 301:187-194, 1978
87. Janssen Pharmaceuticals: International labeling information by the manufacturer, loperamide. Beerse, Belgium.
88. Litovits T, Clancy C, Korberly B, Temple AR, Mann KV: Surveillance of loperamide ingestions: an analysis of 216 poison center reports. Clin Toxicol 35 (1):11-19, 1997
89. Eyssen H, Van Eldere J, Parmentier G, Huijghebaert S, Mertens J: Influence of microbial bile salt desulfation upon the fecal excretion of bile salts in gnotobiotic rats. J Steroid Biochem 22:547-554, 1985
90. Gustafsson BE, Bergström S, Lindstedt S, Norman A: Influence of the diet on the turnover of bile acids in germ-free and conventional rats. Br J Nutr 23:429-442, 1969
91. Oli MW, Petschow BW, Buddington RK: Evaluation of fructo-oligosaccharide supplementation of oral electrolyte solutions for treatment of diarrhea. Recovery of the intestinal bacteria. Dig Dis Sci 43:138-147, 1998
92. Dutriez I, Salés N; Fourni-Zaluski MC, Roques BP: Pre- and post-natal ontogeny of neutral endopeptidase 24-11 ('enkephalinase') studied by in vitro autoradiography in the rat. Experientia 48:290-300, 1992
93. Gorbach SL: Infectious diarrhea and bacterial food poisoning. In Gastrointestinal Disease, Vol 2. WB Saunders Company, Philadelphia, 1993, pp 1128-1189
94. Wingate D, Phillips SF, Lewis SJ, Malagelada J-R, Speelman P, Steffen R, Tytgat GNJ: Guidelines for adults on self-medication for the treatment of acute diarrhoea. Aliment Pharmacol Ther 15:773-782, 2001
95. Dorval ED, Regimbeau C, Gamelin E, Picon L, Berard H: Treatment of acute chemically induced diarrhea by inhibition of enkephalinase. Results of a pilot study. Gastroenterol Clin Biol 19:27-30 1995
96. Ychou M, Douillard JY, Rougier P, Adenis A, Mousseau M, Dufour P, Wendling JL, Burki F, Mignard D, Marty M: Randomized comparison of prophylactic antidiarrheal treatment versus no prophylactic antidiarrheal treatment in patients receiving CPT-11 (irinotecan) for advanced 5-FU-resistant colorectal cancer: an open-label multicenter phase II study. Am J Clin Oncol 23:143-148, 2000
97. Rubio Guerra AF, Lozano Neuvo JJ, Vargas Ayla G, Perez Zenteno AG, Rodriguez Lopez L: Utilidad de la loperamida en el manejo de los patientes con cholera. Med Intern Mex 9 (2):78-80, 1993
98. Salazar-Lindo E, Santisteban-Ponce J, Chea-Woo E, Gutierrez M: Racecadotril in the treatment of acute watery diarrhoea in children. N Engl J Med 343:463-477, 2000
99. Cézard JP, Duhamel JF, Meyer M, Pharaon I, Bellaiche M, Maurage C, Ginies JL, Vaillant JM, Girardet JP, Lamireau T, Poujol A, Morali A, Olives JP, Whately-Smith C, Audrain S, Lecomte JM: Efficacy and tolerability of racecadotril in acute diarrhoea in children. Gastroenterology 120:799-805, 2001
100. Kaplan MA, Prior MJ, McKonly K, DuPont HL, Temple AR, Nelson EB: A multicentre randomised controlled trial of a liquid loperamide product versus placebo in the treatment of acute diarrhoea in children. Clin Paediatr 38:579-591, 1999
101. Rogé J, Baumer H, Berard H, Schwarz JC, Lecompte JM: The enkephalinase inhibitor, acethorphan, in acute diarrhoea; a double-blind controlled trial versus loperamide. Scand J Gastroenterol 28:352-354, 1993
102. Prado D, the Global Adult Racecadotril Study Group: A multinational comparison of racecadotril and loperamide in the treatment of acute watery diarrhoea in adults. Scand J Gastroenterol 37(6):656-661, 2002
103. Hughes IW, UK Janssen Research Group of General Practitioners: First-line treatment in acute non-dysenteric diarrhoea: clinical comparison of loperamide oxide, loperamide and placebo. Br J Cein Pract 49:181-185, 1995
104. Van Den Eynden B, Spaepen W: New approaches to the treatment of patients with acute, nonspecific diarrhoea: a comparison of the effects of loperamide and loperamide oxide. Curr Ther Res 56:1132-1140, 1995
105. Centre for Drug Evaluation and Research, FDA: Guidance for industry: Guidelines for the clinical evaluation of antidiarrhoeal drugs. HEW (FDA) 78-3049, September 1977
106. Lennard-Jones JE: Transit studies: normal results. In Constipation. MA Kamm, JE Lennard-Jonest (eds.). Hampshire, UK, Wrightson Biomedical Publishing, 1994, p. 129
107. Frexinos J, Sallenave J-R: Comparison of loperamide-oxide and acetorphan in acute diarrhoea. Gut 39:A173, 1996
108. Beaugerie L, Baumer P, Chaussade S: Treatment of refractory diarrhoea in AIDS with acetorphan and octreotide: a randomised cross-over study. Eur J Gastroenterol Hepatol 8:485-489, 1996
109. Merrouche Y, Bugat R, Brunet R, Seitz JF, Lucas P, Conroy T, Douillard JY, Bouillet T, Piedbois P, Rougier Ph, Jacob H, Belpomme D, Fabre V, Mery-Mignard D, Mahjoubi M: High dose acetorphan (HDA) versus acetorphan + loperamide (A + L) in the treatment of CPT-11 induced (DD) diarrhea: preliminary report of a randomized phase II study in patients (Pts) with advanced colorectal cancer (CRC). Proc of ASCO 15:211, 1996 (abstract 487)
110. Rogé J, Baumer H, Berard H, Schwarz JC, Lecompte JM: The enkephalinase inhibitor, acethorphan, in acute diarrhoea; a double-blind controlled trial versus loperamide. Scand J Gastroenterol 28:352-354, 1993
111. Kaplan MA, Prior MJ, Ash RR, McKonly KI, Helzner EC, Nelson ED: Loperamide-simethicone vs loperamide alone, simethicone alone, and placebo in the treatment of acute diarrhoea with gas-related abdominal discomfort. Arch Fam Med 8:243-248, 1999
112. Jonsdottir IH, Sjovist A, Lundgren O, Thorén P: Somatic nerve stimulation and cholera-induced net fluid secretion in the small intestine of the rat: evidence for an opioid effect. J Auton Nerv Syst 78:18-23, 1999
113. WHO Diarrhoeal Disease Control Programme. Drugs in the management of acute diarrhoea in infants and young children. Report WHO/CDD/CMT/86.1, 1986